Lupin gets FDA nod for generic Gabapentin Tablets
28 August 2018 | News
It is indicated for the treatment of postherpetic neuralgia in adults
Pharma major Lupin announced that it has received final approval for its Gabapentin Tablets USP, 600 mg and 800 mg from the United States Food and Drug Administration (FDA) to market this drug.
Lupin’s Gabapentin Tablets USP, 600 mg and 800 mg is the generic version of Pfizer’s Neurontin® Tablets, 600 mg and 800 mg.
It is indicated for the treatment of postherpetic neuralgia in adults and adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy.
Gabapentin Tablets USP, 600 mg and 800 mg had annual sales of approximately USD 180.7 million in the US (IQVIA MAT June 2018).
